Could PharmaCan Capital Corp Rise Even More? The Stock Had Another Big Increase Today

 Could PharmaCan Capital Corp Rise Even More? The Stock Had Another Big Increase Today

The stock of PharmaCan Capital Corp (CVE:MJN) is a huge mover today! About 252,024 shares traded hands. PharmaCan Capital Corp (CVE:MJN) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 7 months positive chart setup for the $189.95 million company. It was reported on Nov, 28 by Barchart.com. We have $1.73 PT which if reached, will make CVE:MJN worth $11.40M more.

More notable recent PharmaCan Capital Corp (CVE:MJN) news were published by: Marketwatch.com which released: “Jason Adler Announces Increase in Equity Interest in PharmaCan Capital Corp.” on June 08, 2016, also Midasletter.com with their article: “PharmaCan Capital Corp (TSX.V:MJN) CEO Paul Rosen Interview and Podcast” published on February 20, 2015, Marketwired.com published: “PharmaCan Capital Corp. Announces Approval of Increased Production Expansion …” on April 01, 2015. More interesting news about PharmaCan Capital Corp (CVE:MJN) were released by: Marketwired.com and their article: “PharmaCan Capital Corp. Announces Mortgage Financing Relating to In The Zone …” published on February 05, 2015 as well as Marketwired.com‘s news article titled: “PharmaCan Capital Corp. to Open Toronto Stock Exchange” with publication date: January 13, 2015.

PharmaCan Capital Corp., formerly Searchtech Ventures Inc., is a merchant bank, which is focused on investing in Canada’s medical marijuana industry. The company has a market cap of $189.95 million. The Firm is engaged in the business of investing in companies either licensed or seeking a license to produce medical marijuana. It currently has negative earnings. The Firm operates through two divisions: Investing Segment and Operating Segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment